Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis

Taylor-Cousar, Jennifer L, Robinson, Paul D, Shteinberg, Michal, Downey, Damian G · 2023 · The Lancet

Abstract

Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated from the bench to the bedside have enabled us to potentially treat the basic defect in the majority of children and adults with cystic fibrosis, with a resultant burgeoning adult cystic fibrosis population. However, the long-term effects of these therapies on the multiple manifestations of cystic fibrosis are still under investigation. Understanding the effects of modulators in populations excluded from clinical trials is also crucial. Furthermore, establishing appropriate disease measures to assess efficacy in the youngest potential trial participants and in those whose post-modulator lung function is in the typical range for people without chronic lung disease is essential for continued drug development. Finally, recognising that a health outcome gap has been created for some people and widened for others who are not eligible for, cannot tolerate, or do not have access to modulators is important.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)01609-4

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 128 references

Research works printed but not linked: 2

  1. Zemanick, 2021, A phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one F508del allele, Am J Respir Crit Care Med, 203, 1522, 10.1164/rccm.202102-0509OC · DOI · Paper page
  2. Sawicki, 2015, Rate of uptake of ivacaftor use after US Food and Drug Administration approval among patients enrolled in the US Cystic Fibrosis Foundation patient registry, Ann Am Thorac Soc, 12, 1146

Cited by

See all 174

Metadata

Authors
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G.
Affiliations
  • The University of Queensland (AU)
  • Technion – Israel Institute of Technology (IL)
  • Queen's University Belfast (GB)
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-09
Volume
402
Issue
10408
Pages
1171-1184
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4386565807
Cited by
173
References
128
Citations by year
2026: 55 · 2025: 68 · 2024: 39 · 2023: 10
FWCI
8.01
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords
CFTR modulator therapy, cystic fibrosis, CFTR, adults with cystic fibrosis, long-term drug effects, inclusion and exclusion criteria, drug development, access to treatment
MeSH terms
Adult, Aminophenols, Child, Cystic Fibrosis, Humans, Mutation, Genetic Therapy, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01609-4
The paper
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023). CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. The Lancet. https://doi.org/10.1016/s0140-6736(23)01609-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.